Management of Pemphigus Vulgaris: Challenges and Solutions


Statement of Need

Pemphigus vulgaris (PV) belongs to a group of rare autoimmune mucocutaneous blistering disorders that were often fatal prior to the introduction of effective treatments. There are, as yet, no US guidelines regarding the diagnosis or management of PV. In the absence of a cure, treatments focus on decreasing new blister formation and promoting healing of current blisters/erosions, without causing undue adverse effects. While dermatologists are typically the primary clinicians to diagnose and manage PV, dental clinicians are well-positioned to aid in the diagnosis of PV, since they may be the first HCPs to notice oral lesions that occur in PV. Other clinicians (such as rheumatologists) help administer some of the treatments and assist in the prevention and management of adverse treatment effects. Management has evolved from corticosteroids to steroid-sparing immunosuppressant agents, cyclophosphamide, rituximab, intravenous immunoglobulin, immunoadsorption, and plasmapheresis. Many clinicians would benefit from ongoing education that delineates evidence-based recommendations for management of PV, including how to integrate current and emerging clinical trial data into the decision-making process.

This educational activity provides a unique learning experience reviewing challenges and solutions in the treatment/management of patients with pemphigus vulgaris.  It includes a webinar, patient cases, an interactive infographic and a downloadable image library.

This activity is provided by Global Education Group. UNLV School of Dental Medicine and Paradigm Medical Communications, LLC, are the educational partners.